Ari Azhir

Ari Azhir is a highly experienced executive in the biopharmaceutical industry, currently serving as the Chief Executive Officer of Neuvivo since January 2020, leading efforts in developing therapeutics for Amyotrophic Lateral Sclerosis (ALS) and neurodegenerative diseases. Ari's expertise includes founding and managing several biopharmaceutical companies, such as Neurocea Pharmaceuticals and Neuraltus Pharmaceuticals, with a focus on innovative therapeutics for neurodegenerative disorders. As a member of the UCSF Translational Catalyst Advisory Board, Ari contributes to advancing clinical and translational science. Ari's educational background includes a PhD in Biophysics and dual BSc degrees in Biochemistry and Mathematics from King's College London, complemented by postgraduate studies in Biophysics at the University of Liège.